Singapore, July 30 -- Dr. Falk Pharma GmbH, a Germany-headquartered research-based pharmaceutical company specialising in digestive and metabolic medicine, China's Allianthera (Suzhou) Biopharmaceuticals Co., and its affiliate Allianthera Boston, Inc., a clinical stage biotechnology company focusing on novel drug research and development in immunology and inflammatory diseases, have announced the signing of an agreement on the co-development, license option, manufacturing, and commercialisation of the novel small molecule ATB102, an aryl hydrocarbon receptor (AhR) agonist currently undergoing a phase 1 clinical trial in the United States.

Under the terms of the newly signed agreement, Dr. Falk Pharma and Allianthera will collaborate to d...